CN117643602A - Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine - Google Patents
Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine Download PDFInfo
- Publication number
- CN117643602A CN117643602A CN202211095973.9A CN202211095973A CN117643602A CN 117643602 A CN117643602 A CN 117643602A CN 202211095973 A CN202211095973 A CN 202211095973A CN 117643602 A CN117643602 A CN 117643602A
- Authority
- CN
- China
- Prior art keywords
- raw material
- chrysanthemum
- tea
- weight ratio
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007516 Chrysanthemum Nutrition 0.000 title claims abstract description 58
- 241000205585 Aquilegia canadensis Species 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 28
- 244000189548 Chrysanthemum x morifolium Species 0.000 title abstract 3
- 239000002994 raw material Substances 0.000 claims abstract description 118
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 16
- 241001061264 Astragalus Species 0.000 claims abstract description 15
- 210000004233 talus Anatomy 0.000 claims abstract description 15
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 9
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 9
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 8
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 8
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 8
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 8
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 8
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 7
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 230000036039 immunity Effects 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 6
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 229940107666 astragalus root Drugs 0.000 claims abstract description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 4
- 230000002490 cerebral effect Effects 0.000 claims abstract description 4
- 230000001684 chronic effect Effects 0.000 claims abstract description 4
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 3
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 3
- 238000004140 cleaning Methods 0.000 claims abstract 2
- 241000723353 Chrysanthemum Species 0.000 claims description 55
- 241001122767 Theaceae Species 0.000 claims description 47
- 235000013616 tea Nutrition 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 26
- 230000035622 drinking Effects 0.000 claims description 10
- 238000005485 electric heating Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 235000015091 medicinal tea Nutrition 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 8
- 241000190633 Cordyceps Species 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940000425 combination drug Drugs 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 210000005075 mammary gland Anatomy 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- 240000005373 Panax quinquefolius Species 0.000 abstract description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 5
- 239000006187 pill Substances 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract 3
- 238000010298 pulverizing process Methods 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 241000628997 Flos Species 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 206010035742 Pneumonitis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a ginseng astragalus, honeysuckle, chrysanthemum and cordyceps sinensis combined medicament, which comprises the following raw materials in parts by weight: artificial planted ginseng, american ginseng: the weight ratio of the pseudo-ginseng to the pseudo-ginseng is 1:1.5:1.5; honeysuckle flower: and (3) chrysanthemum: cordyceps sinensis flower (Cordyceps militaris) weight ratio is 2:2:2.5; hawthorn fruit: medlar: astragalus root weight ratio 2.5:3.0:2.5; the preparation method of the invention comprises the following steps: and after the fresh raw materials are respectively collected, cleaning and drying. Pulverizing to 100 mesh respectively. Mixing at a certain weight ratio, and making into medicated tea or tea without medicated residue, honeyed pill or honeyed paste. Or mixing the above materials at a certain weight ratio without pulverizing to obtain tea and medicinal juice. The medicine of the invention is used for improving the immunity of human bodies, resisting pneumonia and chronic pulmonary obstruction caused by infection, treating cerebral apoplexy, treating hypertension, treating hyperlipidemia and treating hyperglycemia.
Description
Technical Field
The invention relates to a specific formula, a manufacturing method and application of a honeysuckle, chrysanthemum and cordyceps sinensis combination drug.
Technical Field
The chrysanthemum and honeysuckle tea in the existing market is a health care product or medicine, has the effects of clearing heat and detoxicating, reducing fire and eliminating dryness, and also has the effects of relieving body heat headache and the like as follows.
1. Flos Chrysanthemi and flos Lonicerae tea can resist influenza virus
The chrysanthemum and honeysuckle tea has certain inhibition effect on various pathogenic bacteria such as staphylococcus aureus, hemolytic streptococcus, escherichia coli, bacillus dysenteriae, vibrio cholerae, typhoid bacillus, paratyphoid bacillus and the like; has antibacterial and bactericidal effects on pneumococcus, meningococcus, green bacillus, tubercle bacillus, shigella dysenteriae, streptococcus mutans, etc., and has inhibitory effects on influenza virus, orphan virus, herpesvirus, leptospira.
2. The chrysanthemum and honeysuckle tea is an environmental sanitation worker for expelling toxin from body "
The chrysanthemum and honeysuckle tea has the effects of resisting inflammation and detoxifying, and has stronger effects of resolving carbuncles and detumescence, clearing heat and detoxifying for carbuncles and furuncles, acute appendicitis and pulmonary carbuncles.
3. Chrysanthemum and honeysuckle tea capable of relieving fever and headache
The chrysanthemum and honeysuckle tea has the effects of dispelling heat and eliminating evil, and has certain effects on external wind-heat or warm disease at the beginning, body heat headache, vexation and insomnia, dark-red tongue, dry throat and mouth, and the like.
4. Flos Chrysanthemi and flos Lonicerae tea can be used for treating sore throat
The chrysanthemum and honeysuckle tea has the effects of cooling blood and relieving dysentery, and has the effects of detoxifying, relieving dysentery, cooling blood and relieving sore throat for dysentery with heat toxin, diarrhea and purulent blood, damp-warm throat obstruction, sore throat and the like.
5. Flos Chrysanthemi and flos Lonicerae tea with effects of relieving summer heat and relieving restlessness
The flos Chrysanthemi and flos Lonicerae tea has effects of clearing heat and detoxicating, dispelling pathogenic wind and heat. Flos Chrysanthemi and flos Lonicerae have effects of clearing heat and toxic materials, relieving sore throat, removing summer-heat, and relieving restlessness.
The chrysanthemum and honeysuckle soaking effect in the existing market is more, and 3 people drink the chrysanthemum and honeysuckle soaking effect rarely.
1. People with deficiency-cold spleen and stomach, fasting diarrhea and constipation are not eating the food as much as possible
People with deficiency-cold spleen and stomach and empty stomach diarrhea and stool pond are uncomfortable in body, the body of the people is in a weak state at the moment, and the body condition of people can be worse when chrysanthemum and honeysuckle are eaten.
2. Example of body cold
Because flos chrysanthemi and honeysuckle are strong in cold property, some women with cold body do not touch the flos chrysanthemi and honeysuckle as much as possible, otherwise pain of the women is aggravated.
3. Pregnant woman with cold womb
The pregnant woman is not good in eating relatively cold foods, and flos chrysanthemi and honeysuckle are foods with strong cold, so that the pregnant woman cannot touch the foods in the cold state, the pregnant woman is not good in body, the health of a fetus is affected, and the pregnant woman and the fetus are kept in mind at a certain time.
In order to eliminate the defects of the honeysuckle and chrysanthemum composition in the existing market and expand the new application of the honeysuckle and chrysanthemum composition, the invention discloses a novel, advanced and practical health-care product or combined medicament of the honeysuckle and chrysanthemum and cordyceps composition.
Disclosure of Invention
The ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combined medicine comprises the following raw materials in parts by weight: the first raw material is planted with American ginseng: notoginseng 1:1.5:1.5 g or 8g of honeysuckle as a second raw material: and (3) chrysanthemum: cordyceps sinensis flower weight ratio 2:2:2.5.6.5 g or 13g of third raw material hawthorn: medlar: astragalus root weight ratio 2.5: 3.0:2.5.8.0 g or 16g
Specifically described are: the mixture types and weight ratios of the first, second and third raw materials are specified to be unchanged; the weight ratio of ingredients of each raw material is specific two data, and the big data is 2 times of the weight of the small data; cordyceps flower is also called Cordyceps militaris and Cordyceps militaris.
The preparation method of the ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combination medicine comprises the following steps:
1. the fresh raw materials are respectively picked or picked, immediately cleaned, and immediately dried by natural sun drying or electric heating vacuum drying or vacuum freeze drying according to the common method until the residual moisture is less than 2 percent.
2. The dried medicinal materials are respectively crushed into 100 meshes.
3. The crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0:6.5:8.0, mixing and stirring uniformly, and subpackaging the weight of 18.5 g+/-1.0 g per packet. Making into medicinal tea which is eaten together with tea residue after 2-3 times a day of tea making and drinking.
4. Or according to the first raw material: the second raw material: the weight ratio of the third raw material is 8.0:13.0:16.0, and subpackaging with weight of 37.0 g+ -1.0 g per packet. Making into medicinal tea without tea residue after tea making three times per day and drinking tea water.
The invention has the advantages that:
1. record in 2015 edition of Chinese pharmacopoeia: ginseng has effects of invigorating primordial qi, restoring pulse and relieving depletion. Tonify spleen and lung, promote fluid production and nourish blood, tranquilize mind and promote intelligence. Can be used for treating asthenia, cold limbs, weak pulse, spleen deficiency, anorexia, lung deficiency, cough with dyspnea, fluid consumption, thirst, internal heat, thirst, deficiency of qi and blood, deficiency of long-term illness, palpitation, insomnia, yang Lougong cold; american ginseng has effects of invigorating qi, nourishing yin, clearing heat and promoting fluid production, and can be used for treating qi deficiency and yin deficiency, dysphoria due to deficiency heat, cough and asthma, phlegm blood, internal heat, diabetes, and dry mouth and throat; cordyceps sinensis flower can regulate yin and yang balance of human body, including regulating yin and yang balance of human body viscera and six viscera, and can be used for treating pulmonary diseases such as emphysema, tracheitis and pneumonia, reducing blood sugar, lowering blood pressure, sterilizing, diminishing inflammation, invigorating kidney, and supporting yang, and can be used for treating female leukorrhagia, metrostaxis, and improving immunity and brain memory; notoginseng radix has effects of removing blood stasis, stopping bleeding, relieving swelling and pain, and can be used for treating hemoptysis, hematemesis, hematochezia, metrorrhagia, traumatic hemorrhage, abdominal pain, and pain due to pricking and traumatic injury; hawthorn has the effects of promoting digestion, invigorating stomach, promoting qi circulation, removing blood stasis, removing turbid pathogen and reducing blood lipid. Can be used for treating food stagnation, gastric and wrist distention, diarrhea, abdominal pain, blood stasis, amenorrhea, puerperal blood stasis, new administration of thorny, chest pain, hernia pain, and hyperlipidemia; the medlar has the effects of nourishing liver and kidney, replenishing vital essence and improving eyesight, and is used for treating consumptive disease, essence deficiency, soreness of waist and knees, dizziness and tinnitus, impotence and spermatorrhea, internal heat and diabetes, blood deficiency and sallow complexion, and dim eyesight; astragalus mongholicus has effects of invigorating qi and yang, consolidating superficial resistance and arresting sweating, inducing diuresis and relieving edema, promoting fluid production and nourishing blood, promoting the circulation of qi and blood, removing obstruction in the body, expelling toxin and pus, healing sore and promoting granulation. Can be used for treating qi deficiency, debilitation, loose stool, depression of middle-jiao, chronic diarrhea, rectocele, hematochezia, metrorrhagia, spontaneous perspiration, qi deficiency, edema, internal heat, diabetes, blood deficiency, sallow complexion, hemiplegia, arthralgia, numbness, carbuncle, ulcer, and chronic ulcer.
2. The ginseng, american ginseng and pseudo-ginseng are combined, the honeysuckle, chrysanthemum and cordyceps sinensis are combined, and the hawthorn, the medlar and the astragalus are added, so that the anti-cold function of the honeysuckle and the chrysanthemum is enhanced, and the functions of resisting cancer, resisting virus, resisting hypertension, resisting hyperlipidemia, resisting hyperglycemia, resisting cardiovascular and cerebrovascular diseases, resisting chronic lung obstruction and resisting stroke are also enhanced.
3. Eliminating taboo of 3 people orally taken honeysuckle and chrysanthemum:
(1) People with deficiency-cold spleen and stomach, fasting diarrhea and constipation are prevented from eating taboo as much as possible;
(2) The oral administration contraindication of women in the case of body cold is impossible:
(3) The pregnant women with cold womb cannot take the medicine orally.
Detailed Description
Example 1
The ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combined medicine comprises the following raw materials in parts by weight: the first raw material is planted with American ginseng: pseudo-ginseng is prepared from honeysuckle serving as a second raw material in a weight ratio of 1:1.5:1.5 g: and (3) chrysanthemum: cordyceps sinensis flower (Cordyceps militaris) weight ratio of 2:2:2.5.6.5 g of third raw material hawthorn: medlar: astragalus root weight ratio 2.5: 3.0:2.5.8.0 g
The preparation method of the ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combination medicine comprises the following steps:
1. the fresh raw materials are respectively picked or picked, immediately cleaned, and immediately dried by natural sun drying or electric heating vacuum drying or vacuum freeze drying according to the common method until the residual moisture is less than 2 percent.
2. The dried medicinal materials are respectively crushed into 100 meshes.
3. The crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0:6.5:8.0, mixing and stirring uniformly, and subpackaging the weight of 18.5 g+/-1.0 g per packet. Making into medicinal tea which is eaten together with tea residue after 2-3 times a day of tea making and drinking.
Example 2
The ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combined medicine comprises the following raw materials in parts by weight: as in example 1;
the preparation method of the ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combination medicine comprises the following steps:
1. the fresh raw materials are respectively picked or picked, immediately cleaned, and immediately dried by natural sun drying or electric heating vacuum drying or vacuum freeze drying according to the common method until the residual moisture is less than 2 percent.
2. The dried medicinal materials are respectively crushed into 100 meshes.
3. The crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: and the third raw material: linolenic acid weight ratio 4.0:6.5:8.0:8.0 raw materials are stirred, mixed and stirred uniformly, and 0.8 to 1.5 weight of pure honey which is the sum of the weight of the raw materials is added, so that the raw materials are frequently prepared into pharmaceutically acceptable honeyed pills or honeyed pastes.
Example 3
The ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combined medicine comprises the following raw materials in parts by weight: the first raw material is planted with American ginseng: pseudo-ginseng is prepared from honeysuckle serving as a second raw material in a weight ratio of 1:1.5:1.5 g: and (3) chrysanthemum: cordyceps sinensis flower (Cordyceps militaris) weight ratio of 2:2:2.5.6.5 g of third raw material hawthorn: medlar: astragalus root weight ratio 2.5: 3.0:2.5.8.0 g
The preparation method of the ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combination medicine comprises the following steps:
1. the fresh raw materials are respectively picked or picked, immediately cleaned, and immediately dried by natural sun drying or electric heating vacuum drying or vacuum freeze drying according to the common method until the residual moisture is less than 2 percent.
2. The dried medicinal materials are respectively crushed into 100 meshes.
3. The crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0:6.5:8.0, and subpackaging with weight of 2x (18.5 g+ -1.0 g) per packet. Making into medicinal tea which is not eaten by tea residue after tea making and drinking for 2-3 times a day.
Example 4
The ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combined medicine comprises the following raw materials in parts by weight: same as in example 3;
the preparation method of the ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combination medicine comprises the following steps:
1. the fresh raw materials are respectively picked or picked, immediately cleaned, and immediately dried by natural sun drying or electric heating vacuum drying or vacuum freeze drying according to the common method until the residual moisture is less than 2 percent.
2. The medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0g:6.5g:8.0g of the mixture is evenly mixed and stirred, and the mixture is subpackaged with the weight of 2x (18.5 g plus or minus 1.0 g) per packet. Making into medicinal tea which is eaten together with tea residue after 2-3 times a day of tea making and drinking. When the chrysanthemum tea is taken orally, chrysanthemum is taken out and is not taken together with other raw materials for tea making, the chrysanthemum is put into another teacup, and the chrysanthemum is soaked in the tea soup at the temperature of 50-60 ℃ of the other raw materials to form the special chrysanthemum tea. The chrysanthemum tea is soaked for 3 times continuously, and the chrysanthemum tea is drunk. The tea residue is not eaten and is poured out.
Example 5
The ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combined medicine comprises the following raw materials in parts by weight: same as in example 3.
The preparation method of the ginseng, astragalus, honeysuckle, chrysanthemum, cordyceps sinensis and flower composition health-care product or combination medicine comprises the following steps:
1. the fresh raw materials are respectively picked or picked, immediately cleaned, and immediately dried by natural sun drying or electric heating vacuum drying or vacuum freeze drying according to the common method until the residual moisture is less than 2 percent.
2. The dried medicinal materials are respectively crushed into 100 meshes.
3. The crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0:6.5:8.0, mixing and stirring evenly, and sub-packaging the mixture with the weight of 18.5g plus or minus 1.0g per small part. Adding linseed oil accounting for 50% of the weight of 18.5 g+/-1.0 g/small part of raw materials, and adding pure honey accounting for 18.5 g+/-1.0 g/small part of raw materials to prepare the ointment for regulating hyperplasia of mammary glands and external application of breast cancer to breasts.
Pharmacodynamic verification test
1. Improving immunity:
1.1 nonspecific immunization: healthy mice, weight 18-20g. Control group 15, 2 times per day with 0.5ml of physiological saline. Inventive drugs examples 1 and 2 were administered orally in groups 2, 15 per group, each time with 4500mg/kg of inventive drug per day, 2 times per day. Inventive drug examples 3 and 4 oral groups 2, 15 per group, were infused with 9000mg/kg of inventive drug each time with 18 g of boiled water for 20 minutes, and then the tea juice was filtered out and infused with stomach 2 times per day. After 10 days, the sample was sacrificed, and the blood rose ring activity was measured by the thymus peptide rose ring activity measurement method (the measurement method is prescribed by the national pharmaceutical standards). The activity of the blood rose is 100% by using physiological saline as a control group. The relative vitality is calculated, and the higher the relative vitality is, the stronger the immunity is. The test results are as follows:
1.2 specific immunization: healthy mice, weight 18-20g. Control group 15, 2 times per day with 0.5ml of physiological saline. The medicine of the invention is administrated orally by 4500mg/kg each time, 15 groups of the medicine are administrated orally by 15 groups, 2 times a day. Inventive drug examples 3 and 4 oral groups 2, 15 per group, were infused with 9000mg/kg of inventive drug each time with 18 g of boiled water for 20 minutes, and then the tea juice was filtered out and infused with stomach 2 times per day. After 15 days, the samples were sacrificed and the average anti-sheep red blood cell antibody titer obtained by the anti-sheep red blood cell antibody test (the test of the experimental animal center) in the blood serum was measured. And the higher the relative titer of each group relative to the anti-sheep red blood cell antibody is calculated by taking the titer of the physiological saline lavage group as 100%, the stronger the immunity is. The test results are as follows:
2. pharmacodynamic test of anti-infective drug:
(1) Animal selection: mice infected with animal experimental models prepared by the experimental animal center, weighing 18-22 g, were randomly grouped into 50 animals per group.
(2) Infection of bacterial species: model mice for pneumonitis caused by staphylococcus aureus and model mice for pneumonitis caused by streptococcus pneumoniae.
(3) Infectious microbe amount: the minimum 100% lethal dose (100% MLD) of the tested strain was determined by the experimental animal center as the infectious agent.
(4) Infection route: the stock solution was diluted to the desired concentration (determined at the center of experimental animals) with 5% gastric membranogen and injected tail vein.
(5) The test method comprises the following steps: mice were divided: A. model mice group of pneumonitis caused by staphylococcus aureus, and two model mice group of pneumonitis caused by streptococcus pneumoniae. The control group to which no drug was administered and the treatment group with the drug of the present invention were carried out. Each group of model animals was 50. Immediately after infection, 5000mg/kg of the medicines of examples 1 and 2 of the present invention were orally administered and once again every 6 hours. Inventive drug examples 3 and 4 oral groups were infused with 9000mg/kg of inventive drug each time with 18 g of boiled water for 20 minutes, followed by filtration of tea juice and 2 times per day. Animal response was observed and mice death was recorded for 7 consecutive days. The medicine and the dosage and the effect are shown in a test result table:
3. treating cerebral apoplexy, lowering blood pressure and blood fat:
selecting Spontaneous Hypertension Rat (SHR) model caused by arteriosclerosis, randomly grouping 20 rats in each group, and effectively reducing blood pressure by more than 20mmHg or to normal blood pressure level after administration for 2 weeks;
selecting a cerebral apoplexy Spontaneous Hypertension Rat (SHRSP) model, randomly grouping 20 rats per group, drinking 21% saline 2 times per day, comparing mortality of a blank control group, a positive drug control group and a drug treatment group of the invention, and administering for 4 weeks;
dosage and method of administration:
examples 1-2 drugs, divided into groups 1-2 in turn; the medicines of examples 1-2 are used in sequence, wherein each dosage is 4500mg/kg, and the medicines are orally taken for 2 times per day; wherein groups 3-4 are prepared by sequentially using the medicines of examples 3-4, 9000mg/kg, brewing with 20 ml of boiled water, filtering to obtain tea juice, and pouring stomach 2 times a day. The tail positive medicine group is 5 th group, is alprostadil for injection of the non-patent technology sold in the prior market, and is administrated by intraperitoneal injection, wherein the dosage of alprostadil is 20 mug/kg emulsion each time, and 2 times per day; the blank group was 6 groups, and was not dosed, with 1% saline 2 times daily.
The test results are shown in the table:
5. pharmacodynamic test of hypoglycemic drugs: the medicine of the invention stimulates insulin secretion, so normal healthy mice are selected, and 15 mice are selected in each group. The experimental mice were dosed once daily after 5 hours of fasting (free drinking). Blood was taken 2 hours after administration, and serum glucose values were determined. The administration was continued for 21 days. The average blood glucose lowering rate (compared to the blank) was calculated. The blood sugar reduction rate is more than 20% effective. The used medicines and dosages and the administration routes are shown in a test result table:
6.23 Conditioning of advanced breast cancer in humans
The 23 patients with advanced breast cancer are ill in hospital, the combined medicine of the invention of the example 2 is taken orally, the medicine of the invention of the example 5 is used for external application on the whole of two breasts, and the breasts without breast cancer lesion are also used for external application for one month to 1 year.
Claims (6)
1. A honeysuckle flower, chrysanthemum and cordyceps sinensis flower combination drug is characterized in that the honeysuckle flower is as follows: and (3) chrysanthemum: the specific weight ratio of the cordyceps flower composition is 2:2:2.5, and the specific total weight of the cordyceps flower composition and the cordyceps flower composition is 6.5g or 13g.
2. The combination drug of specific weight combination of honeysuckle, chrysanthemum and cordyceps sinensis according to claim 1 is characterized by also comprising the following components: the specific weight ratio of the pseudo-ginseng to the hawthorn is 1:1.5:1.5, and the specific total weight of the pseudo-ginseng to the hawthorn is 4g or 8 g: medlar: specific weight ratio of astragalus 2.5:3.0:2.5 and the specific total weight of the three is 8.0g or 16 recombination.
3. The invention discloses a honeysuckle, chrysanthemum and cordyceps sinensis combination drug, which is characterized by comprising the following raw materials in parts by weight:
the first raw material is artificially planted with the under-forest ginseng: notoginseng radix weight ratio of 1:1.5:1.5 g or 8g
The second raw material honeysuckle: and (3) chrysanthemum: cordyceps flower (Cordyceps militaris) weight ratio of 2:2:2.5.6.5 g or 13g
And the third raw material is hawthorn: medlar: astragalus root weight ratio 2.5: 3.0:2.5.8.0 g or 16g
Specifically described are: the mixture types and weight ratios of the first, second and third raw materials are specified to be unchanged; the total weight of ingredients of each raw material of the first, the second and the third is specific two data, and the big data is 2 times of the small data; cordyceps flower is also called Cordyceps militaris, cordyceps militaris.
4. The invention relates to a honeysuckle, chrysanthemum and cordyceps sinensis combination drug, which is characterized by comprising the following steps:
4.1, after the fresh raw materials are respectively picked or extracted, the raw materials are immediately cleaned, and then immediately naturally sun-dried or electric heating vacuum dried or vacuum freeze-dried according to a common method, so that the residual moisture is less than 2 percent.
4.2 the dried medicinal materials are respectively crushed into 100 meshes.
4.3 the crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0:6.5:8.0, mixing and stirring uniformly, and subpackaging the weight of 18.5 g+/-1.0 g per packet. Making into medicinal tea which is eaten together with tea residue after 2-3 times a day of tea making and drinking.
4.4 or according to the first raw material: the second raw material: the weight ratio of the third raw material is 8.0:13.0:16.0, and subpackaging with weight of 37.0 g+ -1.0 g per packet. Making into medicinal tea without tea residue after tea making three times per day and drinking tea water.
4.5 collecting or picking the fresh raw materials respectively, immediately cleaning, and immediately naturally drying by sun or electric heating vacuum drying or vacuum freeze drying according to a common method to achieve residual moisture less than 2%.
4.7 the medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0g:6.5g:8.0g of the mixture is evenly mixed and stirred, and the mixture is subpackaged with the weight of 2x (18.5 g plus or minus 1.0 g) per packet. Making into medicinal tea which is not eaten by tea residue after tea making and drinking for 2-3 times a day. When the chrysanthemum tea is taken orally, chrysanthemum is taken out and is not taken together with other raw materials for tea making, the chrysanthemum is put into another teacup, and the chrysanthemum is soaked in the tea soup at the temperature of 50-60 ℃ of the other raw materials to form the special chrysanthemum tea. The chrysanthemum tea is soaked for 3 times continuously, and the chrysanthemum tea is drunk. The tea residue is not eaten and is poured out.
4.8, after the fresh raw materials are respectively picked or extracted, the raw materials are immediately cleaned, and then immediately naturally sun-dried or electric heating vacuum dried or vacuum freeze-dried according to a common method, so that the residual moisture is less than 2 percent.
4.9 the dried medicinal materials are respectively crushed into 100 meshes.
4.10 the crushed medicinal materials are respectively prepared into a first raw material, a second raw material and a third raw material according to the weight ratio. The raw materials are prepared according to the first raw material: the second raw material: the weight ratio of the third raw material is 4.0:6.5:8.0, mixing and stirring evenly, and sub-packaging the mixture with the weight of 18.5g plus or minus 1.0g per small part. Adding linseed oil accounting for 50% of the weight of 18.5 g+/-1.0 g/small part of raw materials, and adding pure honey accounting for 18.5 g+/-1.0 g/small part of raw materials to prepare the ointment for regulating hyperplasia of mammary glands and external application of breast cancer to breasts.
5. The honeysuckle, chrysanthemum and cordyceps sinensis flower combined medicine according to claim 1, wherein the raw materials are naturally dried by sun or electric heating and vacuum drying or vacuum freeze drying, so that the residual moisture is less than 2%. The dried medicinal materials are respectively crushed to 100 meshes or the raw materials are not crushed.
6. The honeysuckle flower, chrysanthemum and cordyceps sinensis flower combination medicine according to claim 1, which is characterized by being used for improving human immunity, resisting pneumonia and chronic pulmonary obstruction caused by infection, treating cerebral apoplexy, treating hypertension, treating hyperlipidemia, treating hyperglycemia, hyperplasia of mammary glands, breast cancer and other diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211095973.9A CN117643602A (en) | 2022-09-06 | 2022-09-06 | Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211095973.9A CN117643602A (en) | 2022-09-06 | 2022-09-06 | Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117643602A true CN117643602A (en) | 2024-03-05 |
Family
ID=90046576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211095973.9A Pending CN117643602A (en) | 2022-09-06 | 2022-09-06 | Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117643602A (en) |
-
2022
- 2022-09-06 CN CN202211095973.9A patent/CN117643602A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101787432B1 (en) | Method for manufacturing oriental medicine composition which improves menorrhagia and dysmenorrhea comprising fermented velvet antler and yeast hydrolysate | |
| CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN112057551A (en) | Composition with functions of nourishing yin and tonifying kidney and preparation method and application thereof | |
| CN102698106A (en) | Lozenge for clearing heat and relieving sore throat and preparation method of lozenge | |
| CN102988760B (en) | Traditional Chinese medicine composition for treating chlamydia psittaci disease | |
| CN104888007A (en) | Ferment mouthrinse for treating dental ulcer and preparation method thereof | |
| CN107362292A (en) | It is a kind of that there is the composition for improving female genitourinary system inflammation, preparation method and application | |
| CN103893613B (en) | A kind of medicine treating oral ulcer and preparation method | |
| CN102988769B (en) | Traditional Chinese medicine composition for treating chicken coccidiosis and application | |
| CN117643602A (en) | Honeysuckle, chrysanthemum and cordyceps sinensis combined medicine | |
| CN101342331B (en) | Traditional Chinese medicine for treating pulmonitis and upper respiratory tract infection | |
| CN111298020B (en) | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof | |
| CN114404517A (en) | Composition for gout and reducing uric acid and application and preparation method thereof | |
| CN102327304B (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN102631492B (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN106822660A (en) | A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| KR20060029807A (en) | A herb medicine composite for treating dermatitis and a manufacturing process of it | |
| CN113425767B (en) | Traditional Chinese medicine composition for treating pneumonia | |
| CN107233490A (en) | A kind of maca composition of supplementing qi and nourishing yin beautifying face and moistering lotion | |
| CN107854592A (en) | A kind of preparation method for the film for treating oral ulcer that can quickly eliminate pain | |
| CN107692208A (en) | A kind of queen bee Maca tablet and preparation method | |
| CN105309920A (en) | Health product for improving body immunity, and making method thereof | |
| CN105031364A (en) | Preparation for preventing and treating toothache due to wind-fire evil and preparation method of preparation | |
| CN104069472A (en) | Stomatological herbal decoction for treating halitosis caused by damp heat in spleen and stomach and preparation method thereof | |
| CN115624080A (en) | Honeysuckle tea bag and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |